Althea Group Holdings is an ASX-listed global cannabis company specialising in the sales, manufacturing and distribution of pharmaceutical cannabis products and adult use cannabis products. Althea employs roughly 100 people in Australia, the UK, Canada and other parts of the world. The global market for cannabis products is $44bn by the year 2025. The Canadian recreational market is currently valued at $4bn.

Althea Group Holdings through the pharmaceutical brand Althea has fantastic exposure into the leading cannabis markets. Althea brand of pharmaceutical products are currently available in Australia, UK, Germany and is expanding into further markets around the globe including South Africa and shortly France.

Below is an interview with Chief Exec Joshua Fegan who provides an overview of the business, including its growth potential and the expanding global cannabis market